Welcome to our dedicated page for Bristol-Myers Squibb Co news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb Co stock.
Bristol Myers Squibb (NYSE: BMY) generates frequent news across drug development, regulatory milestones, clinical data and corporate actions, reflecting its role as a global biopharmaceutical company focused on serious diseases. News coverage on this page centers on how the company’s cardiovascular, oncology, hematology, immunology and neuroscience programs progress from clinical trials to regulatory decisions and real-world use.
Recent updates have highlighted positive Phase 3 trial results for Camzyos (mavacamten) in adolescents with symptomatic obstructive hypertrophic cardiomyopathy in the SCOUT-HCM study, including statistically significant improvements in left ventricular outflow tract gradients and safety findings consistent with adult experience. Other headlines feature regulatory developments such as the U.S. Food and Drug Administration granting priority review to an Opdivo (nivolumab) plus chemotherapy combination for previously untreated advanced classical Hodgkin lymphoma, and the FDA’s approval of Breyanzi (lisocabtagene maraleucel; liso-cel) for adults with relapsed or refractory marginal zone lymphoma.
Investors and followers of BMY can also expect news on hematology research presented at major medical meetings, including data on investigational targeted protein degradation agents like golcadomide and BMS-986458, and long-term follow-up results for Breyanzi in large B-cell and follicular lymphomas. Corporate and financial items appear as well, such as dividend declarations, debt offerings, tender offers for outstanding notes, and presentations at healthcare investment conferences.
This news feed brings together company press releases, clinical trial readouts, regulatory updates, access and affordability agreements, and SEC-reported events. For users tracking BMY stock, it offers a single place to review how Bristol Myers Squibb’s pipeline, marketed products and capital markets activity evolve over time. Bookmark this page to quickly review new trial results, FDA decisions, access initiatives and financial disclosures related to Bristol Myers Squibb.
Bristol Myers Squibb (NYSE: BMY) announced the FDA's acceptance for priority review of its Biologics License Application for the fixed-dose combination of relatlimab and nivolumab, aimed at treating unresectable or metastatic melanoma in patients aged 12 and older. This combination, assessed during the Phase 2/3 RELATIVITY-047 trial, showed a significant progression-free survival benefit compared to Opdivo alone. The FDA has set a target action date of March 19, 2022. This dual immunotherapy could represent a pivotal advancement in melanoma treatment.
Bristol Myers Squibb (BMY) has received a positive recommendation from the European Medicines Agency's CHMP for the approval of Opdivo (nivolumab) combined with chemotherapy as a first-line treatment for adults with HER2-negative advanced gastric or esophageal cancers with PD-L1 expression (CPS ≥ 5). This follows favorable results from the Phase 3 CheckMate -649 trial, demonstrating significant improvements in overall and progression-free survival compared to chemotherapy alone. The recommendation awaits final approval from the European Commission.
Bristol Myers Squibb announced significant long-term results from the Phase 3 CheckMate -214 trial, revealing a five-year survival rate of 48% for patients with advanced renal cell carcinoma treated with the Opdivo (nivolumab) and Yervoy (ipilimumab) combination. The data showed a median overall survival (OS) of 55.7 months for the combination therapy versus 38.4 months for sunitinib. The study continues to demonstrate durable responses, with ongoing improvements in overall response rates (ORR) and no new safety signals emerging over extended follow-up.
Summary not available.
Bristol Myers Squibb (BMY) announced three-year results from the CheckMate -743 trial, showing significant survival benefits for patients with unresectable malignant pleural mesothelioma treated with Opdivo (nivolumab) and Yervoy (ipilimumab) compared to chemotherapy. After 35.5 months, survival rates were 23% for the immunotherapy group versus 15% for chemotherapy, with median overall survival at 18.1 months versus 14.1 months. The trial demonstrated consistent safety without new signals. These findings will be presented at the 2021 European Society for Medical Oncology Congress.
Bristol Myers Squibb (NYSE: BMY) presented findings at the Heart Failure Society of America Annual Scientific Meeting, indicating that increased mortality risk correlates with worsening New York Heart Association (NYHA) functional class among patients with obstructive hypertrophic cardiomyopathy (HCM). The study, involving 2,495 patients, showed varying mortality rates: 5% for NYHA class I, 9% for class II, and 13% for class III/IV over a median follow-up of 3.9 years. These results underscore the importance of assessing NYHA class in treatment outcomes.
Bristol Myers Squibb (NYSE: BMY) has declared a quarterly dividend of $0.49 per share on its common stock, payable on November 1, 2021, to stockholders of record by October 1, 2021. Additionally, a dividend of $0.50 per share will be paid on its convertible preferred stock on December 1, 2021, for stockholders of record by November 9, 2021. This reflects the company's commitment to returning value to shareholders.
Bristol Myers Squibb (NYSE:BMY) will release its third quarter 2021 financial results on
Bristol Myers Squibb (NYSE:BMY) employee Mark DeLong is participating in the Coast 2 Coast 4 Cancer cycling event, aiming to raise over
Bristol Myers Squibb (NYSE: BMY) announced significant data on immunotherapies at ESMO 2021, showcasing long-term survival benefits of Opdivo (nivolumab) plus Yervoy (ipilimumab) in advanced cancers. Five-year results from CheckMate-214 in renal cell carcinoma and three-year updates from CheckMate-743 in malignant pleural mesothelioma highlight the effectiveness of these treatments. Additional data on the LAG-3 blocking antibody relatlimab combined with nivolumab emphasizes its potential in treating metastatic melanoma. These findings reinforce the role of these therapies in improving patient outcomes.
FAQ
What is the current stock price of Bristol-Myers Squibb Co (BMY)?
What is the market cap of Bristol-Myers Squibb Co (BMY)?
